Personalized mRNA Vaccine Combined With Immunotherapy Cuts Melanoma Recurrence Risk by 42 Percent in Landmark Phase 3 Trial
In a milestone development for oncology and personalized medicine, pharmaceutical giants Merck and Moderna have released the results…
